| 1.68 -0.02 (-1.18%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.26 | 1-year : | 2.6 |
| Resists | First : | 1.93 | Second : | 2.23 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.47 | Second : | 1.22 |
| MAs | MA(5) : | 1.7 |
MA(20) : | 1.84 |
| MA(100) : | 1.36  |
MA(250) : | 1.77 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 7.6 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 6.55 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SCLX ] has closed above bottom band by 14.0%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.7 - 1.71 | 1.71 - 1.72 |
| Low: | 1.59 - 1.6 | 1.6 - 1.61 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Wed, 24 Jul 2024
Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report - GlobeNewswire
Tue, 23 Jul 2024
Scilex Holding Company adds Dr. Annu Navani to Board - Investing.com
Tue, 23 Jul 2024
Scilex Holding Company Strengthens Board of Directors with - GlobeNewswire
Mon, 08 Jul 2024
Scilex Holding Settles Lawsuit, Continues Litigation Against Ex-President - TipRanks
Fri, 05 Jul 2024
Scilex Holding Company Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Fri, 05 Jul 2024
Scilex Holding Company Rings the Closing Bell - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 121 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 34.6 (%) |
| Held by Institutions | 16.1 (%) |
| Shares Short | 8,920 (K) |
| Shares Short P.Month | 7,080 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.79 |
| Profit Margin | -229.5 % |
| Operating Margin | -242.3 % |
| Return on Assets (ttm) | -75 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.38 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 46 (M) |
| PE Ratio | -1.3 |
| PEG Ratio | 0 |
| Price to Book value | -0.94 |
| Price to Sales | 4.32 |
| Price to Cash Flow | -57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|